Chronic Total Occlusion (CTO) Device Market Size, Share & Trends Analysis | Global | 2025-2032 | Includes: Re-entry and Recanalization Devices
Description
Global Chronic Total Occlusion Device Market Report
By iData Research - 87 pages - 6 charts, 23 figures
Executive Summary
The global chronic total occlusion device market was valued at $214 million in 2025. Over the forecast period, the market is expected to grow at a CAGR of 2.7% to reach $257 million by 2032.
The full report suite on the global market for chronic total occlusion, or CTO, devices covers seven geographical regions: North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa. For each region, the report provides detailed market valuation, unit analysis and average selling price data, while also extending projections through 2032 to provide a forward-looking view of market performance. As with the attached example document, this description follows the same proven structure, moving from executive summary through market dynamics, segmentation, competition and strategic report value .
This report focuses on the global CTO device market and includes detailed analysis of re-entry and re-canalization device technologies. It quantifies unit sales, procedure numbers, average selling prices, market size, market shares, growth trends and forecasts through 2032, with historical data to 2022. In addition, the report includes recent mergers and acquisitions, company profiles, product portfolios and analysis of leading competitors.
Overall, the global CTO device market is best understood as a focused enabling technology market. It does not drive the endovascular procedure on its own, but it can make the rest of the procedure possible in the most difficult cases. That role keeps the category important, even as reimbursement challenges, physician conservatism and price sensitivity continue to limit broader expansion.
Market Overview
The global CTO device market includes devices specifically designed to help physicians cross chronic total occlusions during endovascular procedures. These devices are used when a lesion cannot be crossed with a standard guidewire or a hydrophilic guidewire alone. In these situations, dedicated CTO technologies can help create access through or around the occlusion so that other treatment devices can be delivered.
A defining characteristic of this market is the tension between procedural need and physician habit. Some chronic occlusions are clearly too challenging for guidewires alone, and in those cases CTO devices can offer a practical and often necessary solution. However, many specialists still prefer to attempt lesion crossing with conventional guidewires first, both because of familiarity and because of the large price difference between standard wires and dedicated CTO systems. As a result, CTO devices tend to be used selectively rather than routinely.
Because these devices are procedural enablers, market growth is closely linked to the complexity of peripheral vascular intervention. As more patients present with advanced disease, more comorbidities and more calcified lesions, the need for specialized crossing technologies should remain relevant. Still, that relevance does not automatically translate into rapid market growth because cost and reimbursement continue to shape adoption.
Market Drivers
New Indications for CTO Devices
One of the main drivers in the global CTO device market is the expansion of device indications. Becton Dickinson’s Crosser catheter was originally developed and marketed for CTO crossing, but later gained an indication for atherectomy. A similar pattern occurred with Invamed and its Temren atherectomy device with CTO catheter functionality. This is important because atherectomy procedures generally have stronger reimbursement support than CTO crossing alone.
When a device can participate in both a crossing workflow and a reimbursable plaque modification procedure, its value proposition improves. This allows manufacturers to support higher pricing and gives physicians a stronger reason to adopt the product. If more competitors follow this strategy, the CTO device market could benefit from broader functional positioning and better economic justification.
Growth in Endovascular Treatments
CTO device demand is also supported by the growth of endovascular treatment overall. Before a balloon or stent can be deployed, a guidewire must first reach the stenosed or occluded segment. In many procedures this is straightforward, but in more difficult chronic total occlusions, standard guidewires may fail. CTO devices are designed for exactly these situations.
This means the market is tied to total endovascular procedure volume, but especially to growth in more complex cases. As peripheral intervention expands, particularly in patients with advanced disease or with heavy calcification, demand for specialized crossing support rises as well. The market is therefore not only linked to more procedures, but also to more technically difficult procedures.
Responsiveness to BTK Growth and Complex Comorbidities
The CTO device market is particularly responsive to growth in below-the-knee, or BTK, procedures and in patient populations with multiple comorbidities. These patients are more likely to have lesions that are highly calcified, long-segment or otherwise difficult to cross. In such cases, the limitations of standard guidewires become more obvious, increasing the value of a dedicated CTO device.
As diabetic populations continue to grow and as aging patient groups present with more advanced peripheral vascular disease, the need for these enabling technologies should remain stable. Even if only a fraction of total procedures require dedicated crossing support, the absolute number of relevant cases can still rise with procedure volume.
Market Limiters
Lack of Reimbursement
The biggest limiter in the global CTO device market is lack of reimbursement. The cost of a CTO device is high, and in many European countries the use of these devices is not considered a separately reimbursable procedure. When hospitals and physicians are forced to absorb this cost without additional payment, they are more likely to avoid the product unless it is absolutely necessary.
This has a major effect on utilization. Because other treatment pathways remain available for many lesions, physicians often try lower-cost options first. In practice, this means CTO devices are frequently reserved for only the most difficult cases. The lack of reimbursement therefore limits both market size and habit formation, since physicians are less likely to build routine usage patterns around a product that is hard to justify economically.
Patient Selection and Indication Uncertainty
Another key limiter is the lack of clear guidelines around patient selection and the appropriate use of re-entry devices. When physicians do not have strong consensus guidance on when a product should be used, adoption becomes more cautious and selective. This is especially true in technically demanding procedures where learning curves are already longer.
This uncertainty has two effects. First, it narrows the number of cases in which physicians feel comfortable using the device. Second, it discourages some operators from investing the time needed to become highly proficient. In a market where product success depends heavily on physician confidence and experience, this can be a meaningful adoption barrier.
High Cost Relative to Guidewires
High cost relative to guidewires remains a direct and persistent constraint. Standard and hydrophilic guidewires are much cheaper than dedicated re-entry and recanalization systems. Because many lesions can still be crossed with guidewires alone, physicians must be convinced that CTO devices offer enough procedural value to justify the expense.
For some specialists, that case has not yet been fully made. Some remain unconvinced that dedicated CTO devices save enough time or work effectively enough to offset their higher ASP. Since guidewire-based crossing remains common and well understood, switching away from that habit is difficult. This creates a market where product value must be proven repeatedly, case by case.
Market Coverage and Data Scope
Quantitative Coverage
Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.
Qualitative Coverage
Market drivers and limiters, market size and growth trends, recent mergers and acquisitions, company profiles, product portfolios and leading competitors.
Time Frame
Base year 2025, historical data to 2022 and forecasts through 2032.
Regional Coverage
North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa.
Data Types Included
Unit sales, average selling prices, procedure numbers, market size and growth trends.
This report combines detailed quantitative analysis with practical market context, allowing users to evaluate where CTO devices fit within broader endovascular practice and how the category is expected to evolve over time.
Markets Covered and Segmentation
The report covers the Global Chronic Total Occlusion Device Market, further segmented into:
Re-Entry Devices
These devices are designed to help physicians re-enter the true lumen after navigating around a difficult occlusion. They are especially relevant in complex anatomy where subintimal crossing has occurred or where the lesion path requires controlled re-entry.
Re-Canalization Devices
These devices are used to create or support a pathway through the occlusion itself, helping guidewires and other tools advance through heavily stenosed or calcified lesions.
Competitive Analysis
Over the last several years, Medtronic’s position in the CTO device sector has changed significantly. Before August 2013, Medtronic marketed the Pioneer Plus re-entry catheter range, but that product line was later acquired by Volcano. After Medtronic acquired Covidien in January 2015, its presence in the category evolved further. Today, Medtronic promotes the Enteer Re-entry System and the Viance Crossing Catheter, giving it an active role in both re-entry and lesion-crossing workflows. This positions the company as a meaningful competitor with the scale to integrate CTO devices into a broader endovascular offering.
Cardinal Health became a major participant in the CTO device market after acquiring Johnson & Johnson’s Cordis business in March 2015. The company currently markets the Outback re-entry device and the Frontrunner recanalization platform. Cardinal Health benefits from its ability to bundle these CTO products with other endovascular products, which can strengthen account relationships and support competitive positioning. The company also held a dominant position in Europe, with about half of the total market share, making it one of the most important players in the category.
Becton Dickinson strengthened its role in the CTO market through the acquisition of FlowCardia in 2012. That deal brought the Crosser device into BD’s portfolio. The Crosser had already received FDA approval in 2007, and later gained an atherectomy indication in 2011. This added indication was strategically important because physicians do not receive reimbursement specifically for CTO device use, so linking the product to atherectomy created a more defensible value proposition. That helped Becton Dickinson stand out in a market where economic justification is often difficult.
Overall, the competitive landscape is shaped by portfolio bundling, device differentiation and the ability to justify specialized crossing products in a cost-sensitive procedural environment.
Technology and Practice Trends
One of the main trends in the CTO device market is continued innovation in crossing technology. Recanalization and re-entry devices now give physicians more options in how they approach difficult lesions, from image-guided tools to more specialized crossing systems.
Another important trend is the move toward product differentiation through added indications and broader procedural relevance. Devices that can support both CTO crossing and atherectomy-related workflows have a stronger economic position in the market.
Practice patterns also continue to reflect strong dependence on physician preference. Some physicians remain comfortable with guidewire-only approaches, while others increasingly adopt specialized CTO tools in the most difficult lesions. This means product success depends not only on technical performance, but also on training, habit and workflow fit.
Finally, the market benefits from rising endovascular complexity. As more BTK procedures and more calcified lesions enter treatment pathways, the need for advanced crossing support remains relevant even if use is still selective.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Deliverables
87 pages of detailed market analysis, segmentation and forecast data.
6 charts and 23 figures covering market performance, regional trends and competitive positioning.
Methodology Appendix and Acronym Glossary.
Licensing options include single-user, site and enterprise.
Why This Report
Where are the most attractive opportunities in the global CTO device market through 2032?
How are re-entry and re-canalization devices being adopted across different regions and procedural settings?
What role do BTK procedures, calcified lesions and complex comorbidities play in future market growth?
How do high ASPs, lack of reimbursement and physician preference for guidewires limit broader adoption?
Which companies lead the CTO device market, and how are acquisitions and product bundling shaping competition?
How can suppliers better position CTO devices in a market where the clinical role is clear, but the economic case remains challenging?
The Global Chronic Total Occlusion Device Market Report from iData Research answers these questions with detailed segmentation, competitive analysis, pricing data and forecast modeling. Use it to understand category demand, benchmark competitors and support strategy in a specialized but important endovascular device segment.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
By iData Research - 87 pages - 6 charts, 23 figures
Executive Summary
The global chronic total occlusion device market was valued at $214 million in 2025. Over the forecast period, the market is expected to grow at a CAGR of 2.7% to reach $257 million by 2032.
The full report suite on the global market for chronic total occlusion, or CTO, devices covers seven geographical regions: North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa. For each region, the report provides detailed market valuation, unit analysis and average selling price data, while also extending projections through 2032 to provide a forward-looking view of market performance. As with the attached example document, this description follows the same proven structure, moving from executive summary through market dynamics, segmentation, competition and strategic report value .
This report focuses on the global CTO device market and includes detailed analysis of re-entry and re-canalization device technologies. It quantifies unit sales, procedure numbers, average selling prices, market size, market shares, growth trends and forecasts through 2032, with historical data to 2022. In addition, the report includes recent mergers and acquisitions, company profiles, product portfolios and analysis of leading competitors.
Overall, the global CTO device market is best understood as a focused enabling technology market. It does not drive the endovascular procedure on its own, but it can make the rest of the procedure possible in the most difficult cases. That role keeps the category important, even as reimbursement challenges, physician conservatism and price sensitivity continue to limit broader expansion.
Market Overview
The global CTO device market includes devices specifically designed to help physicians cross chronic total occlusions during endovascular procedures. These devices are used when a lesion cannot be crossed with a standard guidewire or a hydrophilic guidewire alone. In these situations, dedicated CTO technologies can help create access through or around the occlusion so that other treatment devices can be delivered.
A defining characteristic of this market is the tension between procedural need and physician habit. Some chronic occlusions are clearly too challenging for guidewires alone, and in those cases CTO devices can offer a practical and often necessary solution. However, many specialists still prefer to attempt lesion crossing with conventional guidewires first, both because of familiarity and because of the large price difference between standard wires and dedicated CTO systems. As a result, CTO devices tend to be used selectively rather than routinely.
Because these devices are procedural enablers, market growth is closely linked to the complexity of peripheral vascular intervention. As more patients present with advanced disease, more comorbidities and more calcified lesions, the need for specialized crossing technologies should remain relevant. Still, that relevance does not automatically translate into rapid market growth because cost and reimbursement continue to shape adoption.
Market Drivers
New Indications for CTO Devices
One of the main drivers in the global CTO device market is the expansion of device indications. Becton Dickinson’s Crosser catheter was originally developed and marketed for CTO crossing, but later gained an indication for atherectomy. A similar pattern occurred with Invamed and its Temren atherectomy device with CTO catheter functionality. This is important because atherectomy procedures generally have stronger reimbursement support than CTO crossing alone.
When a device can participate in both a crossing workflow and a reimbursable plaque modification procedure, its value proposition improves. This allows manufacturers to support higher pricing and gives physicians a stronger reason to adopt the product. If more competitors follow this strategy, the CTO device market could benefit from broader functional positioning and better economic justification.
Growth in Endovascular Treatments
CTO device demand is also supported by the growth of endovascular treatment overall. Before a balloon or stent can be deployed, a guidewire must first reach the stenosed or occluded segment. In many procedures this is straightforward, but in more difficult chronic total occlusions, standard guidewires may fail. CTO devices are designed for exactly these situations.
This means the market is tied to total endovascular procedure volume, but especially to growth in more complex cases. As peripheral intervention expands, particularly in patients with advanced disease or with heavy calcification, demand for specialized crossing support rises as well. The market is therefore not only linked to more procedures, but also to more technically difficult procedures.
Responsiveness to BTK Growth and Complex Comorbidities
The CTO device market is particularly responsive to growth in below-the-knee, or BTK, procedures and in patient populations with multiple comorbidities. These patients are more likely to have lesions that are highly calcified, long-segment or otherwise difficult to cross. In such cases, the limitations of standard guidewires become more obvious, increasing the value of a dedicated CTO device.
As diabetic populations continue to grow and as aging patient groups present with more advanced peripheral vascular disease, the need for these enabling technologies should remain stable. Even if only a fraction of total procedures require dedicated crossing support, the absolute number of relevant cases can still rise with procedure volume.
Market Limiters
Lack of Reimbursement
The biggest limiter in the global CTO device market is lack of reimbursement. The cost of a CTO device is high, and in many European countries the use of these devices is not considered a separately reimbursable procedure. When hospitals and physicians are forced to absorb this cost without additional payment, they are more likely to avoid the product unless it is absolutely necessary.
This has a major effect on utilization. Because other treatment pathways remain available for many lesions, physicians often try lower-cost options first. In practice, this means CTO devices are frequently reserved for only the most difficult cases. The lack of reimbursement therefore limits both market size and habit formation, since physicians are less likely to build routine usage patterns around a product that is hard to justify economically.
Patient Selection and Indication Uncertainty
Another key limiter is the lack of clear guidelines around patient selection and the appropriate use of re-entry devices. When physicians do not have strong consensus guidance on when a product should be used, adoption becomes more cautious and selective. This is especially true in technically demanding procedures where learning curves are already longer.
This uncertainty has two effects. First, it narrows the number of cases in which physicians feel comfortable using the device. Second, it discourages some operators from investing the time needed to become highly proficient. In a market where product success depends heavily on physician confidence and experience, this can be a meaningful adoption barrier.
High Cost Relative to Guidewires
High cost relative to guidewires remains a direct and persistent constraint. Standard and hydrophilic guidewires are much cheaper than dedicated re-entry and recanalization systems. Because many lesions can still be crossed with guidewires alone, physicians must be convinced that CTO devices offer enough procedural value to justify the expense.
For some specialists, that case has not yet been fully made. Some remain unconvinced that dedicated CTO devices save enough time or work effectively enough to offset their higher ASP. Since guidewire-based crossing remains common and well understood, switching away from that habit is difficult. This creates a market where product value must be proven repeatedly, case by case.
Market Coverage and Data Scope
Quantitative Coverage
Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.
Qualitative Coverage
Market drivers and limiters, market size and growth trends, recent mergers and acquisitions, company profiles, product portfolios and leading competitors.
Time Frame
Base year 2025, historical data to 2022 and forecasts through 2032.
Regional Coverage
North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa.
Data Types Included
Unit sales, average selling prices, procedure numbers, market size and growth trends.
This report combines detailed quantitative analysis with practical market context, allowing users to evaluate where CTO devices fit within broader endovascular practice and how the category is expected to evolve over time.
Markets Covered and Segmentation
The report covers the Global Chronic Total Occlusion Device Market, further segmented into:
Re-Entry Devices
These devices are designed to help physicians re-enter the true lumen after navigating around a difficult occlusion. They are especially relevant in complex anatomy where subintimal crossing has occurred or where the lesion path requires controlled re-entry.
Re-Canalization Devices
These devices are used to create or support a pathway through the occlusion itself, helping guidewires and other tools advance through heavily stenosed or calcified lesions.
Competitive Analysis
Over the last several years, Medtronic’s position in the CTO device sector has changed significantly. Before August 2013, Medtronic marketed the Pioneer Plus re-entry catheter range, but that product line was later acquired by Volcano. After Medtronic acquired Covidien in January 2015, its presence in the category evolved further. Today, Medtronic promotes the Enteer Re-entry System and the Viance Crossing Catheter, giving it an active role in both re-entry and lesion-crossing workflows. This positions the company as a meaningful competitor with the scale to integrate CTO devices into a broader endovascular offering.
Cardinal Health became a major participant in the CTO device market after acquiring Johnson & Johnson’s Cordis business in March 2015. The company currently markets the Outback re-entry device and the Frontrunner recanalization platform. Cardinal Health benefits from its ability to bundle these CTO products with other endovascular products, which can strengthen account relationships and support competitive positioning. The company also held a dominant position in Europe, with about half of the total market share, making it one of the most important players in the category.
Becton Dickinson strengthened its role in the CTO market through the acquisition of FlowCardia in 2012. That deal brought the Crosser device into BD’s portfolio. The Crosser had already received FDA approval in 2007, and later gained an atherectomy indication in 2011. This added indication was strategically important because physicians do not receive reimbursement specifically for CTO device use, so linking the product to atherectomy created a more defensible value proposition. That helped Becton Dickinson stand out in a market where economic justification is often difficult.
Overall, the competitive landscape is shaped by portfolio bundling, device differentiation and the ability to justify specialized crossing products in a cost-sensitive procedural environment.
Technology and Practice Trends
One of the main trends in the CTO device market is continued innovation in crossing technology. Recanalization and re-entry devices now give physicians more options in how they approach difficult lesions, from image-guided tools to more specialized crossing systems.
Another important trend is the move toward product differentiation through added indications and broader procedural relevance. Devices that can support both CTO crossing and atherectomy-related workflows have a stronger economic position in the market.
Practice patterns also continue to reflect strong dependence on physician preference. Some physicians remain comfortable with guidewire-only approaches, while others increasingly adopt specialized CTO tools in the most difficult lesions. This means product success depends not only on technical performance, but also on training, habit and workflow fit.
Finally, the market benefits from rising endovascular complexity. As more BTK procedures and more calcified lesions enter treatment pathways, the need for advanced crossing support remains relevant even if use is still selective.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Deliverables
87 pages of detailed market analysis, segmentation and forecast data.
6 charts and 23 figures covering market performance, regional trends and competitive positioning.
Methodology Appendix and Acronym Glossary.
Licensing options include single-user, site and enterprise.
Why This Report
Where are the most attractive opportunities in the global CTO device market through 2032?
How are re-entry and re-canalization devices being adopted across different regions and procedural settings?
What role do BTK procedures, calcified lesions and complex comorbidities play in future market growth?
How do high ASPs, lack of reimbursement and physician preference for guidewires limit broader adoption?
Which companies lead the CTO device market, and how are acquisitions and product bundling shaping competition?
How can suppliers better position CTO devices in a market where the clinical role is clear, but the economic case remains challenging?
The Global Chronic Total Occlusion Device Market Report from iData Research answers these questions with detailed segmentation, competitive analysis, pricing data and forecast modeling. Use it to understand category demand, benchmark competitors and support strategy in a specialized but important endovascular device segment.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
Table of Contents
71 Pages
- List Of Figures
- List Of Charts
- Research Methodology
- Step 1: Project Initiation & Team Selection
- Step 2: Prepare Data Systems And Perform Secondary Research
- Step 3: Preparation For Interviews & Questionnaire Design
- Step 4: Performing Primary Research
- Step 5: Research Analysis: Establishing Baseline Estimates
- Step 6: Market Forecast And Analysis
- Step 7: Identify Strategic Opportunities
- Step 8: Final Review And Market Release
- Step 9: Customer Feedback And Market Monitoring
- Impact Of Global Tariffs
- Chronic Total Occlusion Device Market
- 9.1 Executive Summary
- 9.1.1 Global Chronic Total Occlusion Device Market Overview
- 9.1.2 Competitive Analysis
- 9.1.3 Procedures Included
- 9.1.4 Markets Included
- 9.1.5 Regions Included
- 9.2 Introduction
- 9.3 Procedure Numbers
- 9.3.1 Total Cto Procedures
- 9.3.2 Re-Entry Procedures
- 9.3.3 Recanalization Procedures
- 9.4 Market Overview
- 9.4.1 By Segment
- 9.4.2 By Region
- 9.5 Market Analysis And Forecast
- 9.5.1 Total Chronic Total Occlusion Device Market
- 9.5.2 Re-Entry Device Market
- 9.5.3 Recanalization Device Market
- 9.6 Drivers And Limiters
- 9.6.1 Market Drivers
- 9.6.2 Market Limiters
- 9.7 Competitive Market Share Analysis
- Abbreviations
- Chart 9-1: CTO Device Market, Global, 2025 & 2032
- Chart 9-2: CTO Procedures, Global, 2025
- Chart 9-3: CTO Procedures by Region, Global, 2022 – 2032
- Chart 9-4: CTO Device Market by Segment, Global, 2022 – 2032
- Chart 9-5: CTO Device Market by Region, Global, 2022 – 2032
- Chart 9-6: Leading Competitors, CTO Device Market, Global, 2025
- Figure 9-1: CTO Device Procedures Covered
- Figure 9-2: CTO Device Markets Covered
- Figure 9-3: CTO Device Regions Covered, Global (1 of 2)
- Figure 9-4: CTO Device Regions Covered, Global (2 of 2)
- Figure 9-5: CTO Procedures by Segment, Global, 2022 – 2032
- Figure 9-6: CTO Procedures by Region, Global, 2022 – 2032
- Figure 9-7: CTO Procedures by Country, North America, 2022 – 2032
- Figure 9-8: CTO Procedures by Country, Latin America, 2022 – 2032 (1 of 2)
- Figure 9-9: CTO Procedures by Country, Latin America, 2022 – 2032 (2 of 2)
- Figure 9-10: CTO Procedures by Country, Western Europe, 2022 – 2032
- Figure 9-11: CTO Procedures by Country, Central & Eastern Europe, 2022 – 2032 (1 of 2)
- Figure 9-12: CTO Procedures by Country, Central & Eastern Europe, 2022 – 2032 (2 of 2)
- Figure 9-13: CTO Procedures by Country, Middle East, 2022 – 2032
- Figure 9-14: CTO Procedures by Country, Asia-Pacific, 2022 – 2032 (1 of 3)
- Figure 9-15: CTO Procedures by Country, Asia-Pacific, 2022 – 2032 (2 of 3)
- Figure 9-16: CTO Procedures by Country, Asia-Pacific, 2022 – 2032 (3 of 3)
- Figure 9-17: CTO Procedures by Country, Africa, 2022 – 2032
- Figure 9-18: Re-Entry Procedures by Region, Global, 2022 – 2032
- Figure 9-19: Re-Entry Procedures by Country, North America, 2022 – 2032
- Figure 9-20: Re-Entry Procedures by Country, Latin America, 2022 – 2032 (1 of 2)
- Figure 9-21: Re-Entry Procedures by Country, Latin America, 2022 – 2032 (2 of 2)
- Figure 9-22: Re-Entry Procedures by Country, Western Europe, 2022 – 2032
- Figure 9-23: Re-Entry Procedures by Country, Central & Eastern Europe, 2022 – 2032 (1 of 2)
- Figure 9-24: Re-Entry Procedures by Country, Central & Eastern Europe, 2022 – 2032 (2 of 2)
- Figure 9-25: Re-Entry Procedures by Country, Middle East, 2022 – 2032
- Figure 9-26: Re-Entry Procedures by Country, Asia-Pacific, 2022 – 2032 (1 of 3)
- Figure 9-27: Re-Entry Procedures by Country, Asia-Pacific, 2022 – 2032 (2 of 3)
- Figure 9-28: Re-Entry Procedures by Country, Asia-Pacific, 2022 – 2032 (3 of 3)
- Figure 9-29: Re-Entry Procedures by Country, Africa, 2022 – 2032
- Figure 9-30: Recanalization Procedures by Region, Global, 2022 – 2032
- Figure 9-31: Recanalization Procedures by Country, North America, 2022 – 2032
- Figure 9-32: Recanalization Procedures by Country, Latin America, 2022 – 2032 (1 of 2)
- Figure 9-33: Recanalization Procedures by Country, Latin America, 2022 – 2032 (2 of 2)
- Figure 9-34: Recanalization Procedures by Country, Western Europe, 2022 – 2032
- Figure 9-35: Recanalization Procedures by Country, Central & Eastern Europe, 2022 – 2032 (1 of 2)
- Figure 9-36: Recanalization Procedures by Country, Central & Eastern Europe, 2022 – 2032 (2 of 2)
- Figure 9-37: Recanalization Procedures by Country, Middle East, 2022 – 2032
- Figure 9-38: Recanalization Procedures by Country, Asia-Pacific, 2022 – 2032 (1 of 3)
- Figure 9-39: Recanalization Procedures by Country, Asia-Pacific, 2022 – 2032 (2 of 3)
- Figure 9-40: Recanalization Procedures by Country, Asia-Pacific, 2022 – 2032 (3 of 3)
- Figure 9-41: Recanalization Procedures by Country, Africa, 2022 – 2032
- Figure 9-42: CTO Device Market by Segment, Global, 2022 – 2032 (US$M)
- Figure 9-43: CTO Device Market by Region, Global, 2022 – 2032 (US$M)
- Figure 9-44: Total CTO Device Market, Global, 2022 – 2032
- Figure 9-45: Units Sold by Region, CTO Device Market, Global, 2022 – 2032
- Figure 9-46: Average Selling Price by Region, CTO Device Market, Global, 2022 – 2032 (US$)
- Figure 9-47: Market Value by Region, CTO Device Market, Global, 2022 – 2032 (US$M)
- Figure 9-48: Re-Entry Device Market, Global, 2022 – 2032
- Figure 9-49: Units Sold by Region, Re-Entry Device Market, Global, 2022 – 2032
- Figure 9-50: Average Selling Price by Region, Re-Entry Device Market, Global, 2022 – 2032 (US$)
- Figure 9-51: Market Value by Region, Re-Entry Device Market, Global, 2022 – 2032 (US$M)
- Figure 9-52: Recanalization Device Market, Global, 2022 – 2032
- Figure 9-53: Units Sold by Region, Recanalization Device Market, Global, 2022 – 2032
- Figure 9-54: Average Selling Price by Region, Recanalization Device Market, Global, 2022 – 2032 (US$)
- Figure 9-55: Market Value by Region, Recanalization Device Market, Global, 2022 – 2032 (US$M)
- Figure 9-56: Leading Competitors, CTO Device Market, Global, 2025
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
